TuisGRF • BME
add
Grifols SA Class A
Vorige sluiting
€10,89
Dagwisseling
€10,75 - €10,93
Jaarwisseling
€7,32 - €13,70
Markkapitalisasie
6,67Â mjd EUR
Gemiddelde volume
1,54Â m
P/V-verhouding
19,96
Dividend-opbrengs
1,38%
PrimĂŞre beurs
BME
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (EUR) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,87Â mjd | 4,04% |
Bedryfskoste | 370,34Â m | -1,71% |
Netto inkomste | 126,96Â m | 145,62% |
Netto winsgrens | 6,81 | 136,46% |
Wins per aandeel | — | — |
EBITDA | 484,03Â m | 3,41% |
Effektiewe belastingkoers | 27,61% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (EUR) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 825,48Â m | 2,32% |
Totale bates | 19,85Â mjd | -2,12% |
Totale aanspreeklikheid | 12,31Â mjd | 0,14% |
Totale ekwiteit | 7,55 mjd | — |
Uitstaande aandele | 680,51 m | — |
Prys om te bespreek | 1,43 | — |
Opbrengs op bates | 4,81% | — |
Opbrengs op kapitaal | 5,53% | — |
Kontantvloei
Netto kontantverandering
| (EUR) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 126,96Â m | 145,62% |
Kontant van bedrywe | 325,40Â m | 8,61% |
Kontant van beleggings | -122,68Â m | 37,53% |
Kontant van finansiering | -138,76Â m | 91,08% |
Netto kontantverandering | 62,27Â m | 104,24% |
Beskikbare kontantvloei | 369,19Â m | 37,66% |
Meer oor
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
HUB
Gestig
18 Nov. 1940
Webwerf
Werknemers
23Â 800